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Abstract
Randomisation is used in experimental design
to reduce the prevalence of unanticipated con-
founders. Complete randomisation can how-
ever create unbalanced designs, for example,
grouping all samples of the same condition in
the same batch. Block randomisation is an ap-
proach that can prevent severe imbalances in
sample allocation with respect to both known
and unknown confounders. This feature pro-
vides the reader with an introduction to block-
ing and randomisation, insights into how to ef-
fectively organise samples during experimental
design, with special considerations with respect
to proteomics.
Introduction
A vital part of experimental design consists of
defining the order of sample processing and, if
necessary, the creation of batches. The aim is
then to avoid the introduction of confounders
that would bias the interpretation of the data.
One of the most famous examples of a con-
founded experiment is the observation of “water
memory” by Davenas et al.,1 i.e. the claimed
ability of water to retain a memory of sub-
stances previously dissolved in it, which could
not be replicated in a double-blinded experi-
mental design,2 suggesting that the initial data
were the results of experimenter bias. Flaws in
experimental design and unintended confound-
ing can also be found in proteomics literature,
as shown in e.g. Sorace and Zhan,3 Hu et al.,4
Morris et al.,5 and Mertens.6 Knowing how to
deal with the challenges of experimental design
is therefore central to achieving reproducible
experiments. For a general introduction to ex-
perimental design, see for example Box et al.,7
Ruxton and Colegrave,8 Lawson,9 and for pro-
teomics specifically, see Burzykowski et al.10
and Maes et al.11
While some common confounders, like sam-
ple annotation, date and order of processing,
and their associated solutions are generic, oth-
ers are more field-specific. In proteomics, the
use of liquid-chromatography systems coupled
to mass spectrometers (LC-MS) notably poses
major challenges in terms of long-term perfor-
mance and influence by outside factors.12 Sim-
ilarly, there can be differences introduced, no-
tably during protein digestion,13 peptide frac-
tionation and enrichment,14 and data inter-
pretation.15 A good experimental design must
therefore take into account both generic and
field-specific confounders, which can be ex-
tremely complex in larger experiments. This is
especially challenging when experiments com-
bine multiple analytical readouts, and when the
allocation of patients to treatment arms and
sample collection may be constrained.
Given the constraints of an experiment, the
goal of defining sample order and batches is to
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a) minimise the influence of anticipated con-
founders, b) mitigate the risk that unantici-
pated confounders bias the interpretation of the
results, and c) ensure that the results remain in-
terpretable if something does not go as planned
and, for example, a batch is lost.
Sample randomisation
Deciphering the association between sample
characteristics, e.g. tumour types, and the pro-
teome holds the key for improved diagnostic
and treatment of diseases. In this setting, pro-
tein abundances are the responses, or outcome
variables, of the experiment, and the other vari-
ables in the model are the explanatory vari-
ables.11,16,17 Often, one is interested in study-
ing the association of one or more explanatory
variable(s) with the response(s), while having
to control for other explanatory variables that
are not of primary interest. The explanatory
variables of interest are also referred to as treat-
ment variables, e.g. treatment, disease status,
or tumour type.
The variables included in the model because
they are expected to potentially influence the
outcome, although not being of primary inter-
est, are referred to as control variables, and in-
clude properties such as enzyme batch, column,
or day of acquisition. Note that some vari-
ables may belong in either category, depend-
ing on the goals of the experiment, e.g. age,
sex, and patient ancestry. If there is an associ-
ation between treatment and control variables,
this can impair the ability to estimate the ef-
fect of the treatment variable. In an extreme
case, if Controls are handled first, and Patients
last, to what extent are the observed differences
between patients and controls genuine and not
artefacts introduced during sample handling?
In addition to the monitored variables in-
cluded in the model, other variables may also
affect the results, such as machine drift or en-
vironmental changes during the analysis. Ob-
viously one cannot control for all variables that
may have an influence on the response variable.
By their nature, unobserved variables cannot
be included in the model as they are not ob-
served, and including too many variables in the
model reduces the power of the experiment. A
high number of samples combined with ran-
domisation provides a safeguard, in the long
run, against undue influence of unobserved vari-
ables.7,18,19 For more details on the importance
of randomisation in proteomics, please see Mor-
ris et al.5 and Mertens.6
To illustrate the effects of randomised versus
ordered allocation, let us assume that we have
ten patients receiving a given Treatment and
ten a Placebo, with the treatment resulting in
a minor mean increase in the analytical read-
out — e.g. the abundance of a given protein,
see Figure 1. Figure 1A shows the experimental
setting for the ordered allocation with Placebo
subjects processed first, while Figure 1E shows
the same subjects in a complete randomised al-
location. The ‘true’ protein abundance for each
patient is plotted in Figures 1B and F for the
ordered and complete randomised allocations,
respectively. Note that, apart from the order of
the samples, these figures are exactly the same.
Now let us introduce a machine drift (Fig-
ures 1C and G) that causes the mass spec-
trometer to detect slightly less of the protein
over time. For the ordered allocation, the ob-
served protein abundances show almost no dif-
ference between the two group means (Figure
1D). Conversely, the difference in group means
for the randomised allocation is nearly the same
as the ‘true’ difference (Figure 1G), and only
has added variance caused by the machine drift.
Note that if the groups were reversed in the
ordered sample allocation scheme, the group
mean difference would have been exaggerated
instead.
Block randomisation
Complete randomisation can produce severely
unbalanced sample allocations, e.g. randomly
assigning all subjects receiving treatment to one
batch and all subjects receiving placebo to an-
other batch. Then, batch and treatment are
completely confounded, and it is impossible to
perform an analysis with regards to the treat-
ment. In such a situation it is not uncommon to
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Figure 1: Randomisation to account for machine drift. A, E, I: Sample allocation order for 10
subjects receiving placebo (black figures, subjects 1 – 10) and treatment (red figures, subjects 11
– 20); ordered allocation (A), complete randomisation (E), and block randomisation (I). B, F,
J: True abundance for the subjects if there would be no machine drift; ordered allocation (B),
complete randomisation (F), and block randomisation (J), (identical except for the sample order).
C, G, K: Simulated machine drift, identical for all three settings. D, H, L: Observed abundances
= true abundance + machine drift; ordered allocation (D), complete randomisation (H), and block
randomisation (L). Dashed lines indicate the group means for each setting.
resort to adjusting batches and sample ordering
manually, or simply “randomise until it looks
good”. Both of these procedures are poorly
reproducible, and potentially introduce unin-
tended biases. A structured way to solve this
problem is to rather rely on block randomisa-
tion.20
As a simple example, let us revisit the ex-
perimental setting from Figure 1. To ensure
that both treatments are equally represented
throughout the run, we make ten blocks of two
subjects: one Treatment and the other Placebo.
These are the smallest blocks we can make
where each treatment is proportionally repre-
sented. The order of the treatments within
the blocks (Treatment first or Placebo first) is
chosen randomly for each block. Finally the
subjects are randomly assigned to the blocks
(see the right panels of Figure 1). Thus, we
group small, representative subsets of the ex-
periment together (the blocks), but within the
blocks the order of the treatments is random,
and within these constraints the assignment
of subjects to blocks is also random. Conse-
quently, while in complete randomisation all
sample sequences are possible, block randomi-
sation returns a sample sequence from a sub-
set of all possible sequences where, by design,
biases introduced by sequential processing are
distributed as evenly as possible over the treat-
ment groups.
In practice, it is not always possible or prefer-
able to have the same number of subjects in
all groups of the treatment variable(s).18,19 The
block randomisation procedure with groups of
different sizes is only slightly different. As be-
fore, first, blocks of samples where each group
is proportionally represented are created. For
example, if one group is twice as large as the
other group, each block would consist of three
subjects, one of the smaller group and two of
the larger group (Figure 2A). When the groups
do not have a small common divisor, one can
create blocks of different sizes. For example, in
a nine vs. ten setting, one would make eight
blocks consisting of one subject of each group,
and one block with the remaining three sub-
jects (Figure 2B). In an experiment with mul-
tiple treatment levels, e.g. Placebo, Treatment
1, and Treatment 2, the blocks would consist
of subjects from all treatments. As previously,
the blocks are put in random order, the order of
3
the treatments within the blocks is chosen ran-
domly for each block, and subjects are finally
randomly allocated according to their charac-
teristics.
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Figure 2: Examples of block randomisation. A:
16 subjects receiving placebo (black, subjects
1 – 16) and eight treatment (red, subjects 17
– 24), results in eight blocks of three subjects,
each containing two Placebo and one Treatment.
Subjects are randomly assigned to a block and
the order within each block is randomised. B:
10 subjects receiving placebo (black, subjects 1
– 10) and nine treatment (red, subjects 11 – 19),
results in one block of three subjects, contain-
ing two Placebo and one Treatment, and eight
blocks of two subjects, containing one Placebo
and one Treatment. The block containing three
subjects is randomly placed among the other
blocks. Subjects are randomly assigned to a
block and the order of the subjects within each
block is randomised.
Accounting for control vari-
ables
The previous examples included two groups of
subjects where the treatment was assumed to
be the only difference, and where all samples
could be processed at the same time. Most ex-
periments have to account for control variables
when estimating the treatment effects. Some
common control variables are technical in na-
ture, such as protease batches, freezer locations,
and biobanks, but sample characteristics such
as sex, age, and patient ancestry also commonly
fall into this category. As the complexity of the
design increases, it is common that not all sam-
ples can be processed at the same time in the
same way at the same location. The sets of
samples created by this process are referred to
as batches, and this becomes yet another con-
trol variable to account for.
It is important to distribute, as best one can,
the different levels of the treatment variables
equally over the different levels of the control
variables. In case of substantial confounding, as
when most of the subjects receiving Placebo are
Female and most of those receiving the Treat-
ment are Male, it can become impossible to
estimate the treatment effect. Similarly, when
all Treatment subjects are in one batch and all
Placebo in the other, batch and treatment are
confounded and without a batch-independent
reference it is not possible to distinguish the
treatment effect from a possible batch effect.
Thus, it is important to account for control vari-
ables in the experimental design and in the sam-
ple organisation, and this can also be achieved
using block randomisation.
As a simple example, let us reuse the experi-
mental setting from Figure 1, but this time split
the experiment into two batches, e.g. due to
different days of processing. Given that both
treatment groups have ten subjects each, it is
possible to divide both treatment groups into
two subgroups of equal size. The first batch,
Batch A, consists of five randomly chosen sub-
jects from the Treatment group plus five ran-
domly chosen subjects from the Placebo group,
while the second batch, Batch B, consists of the
remaining subjects (Figure 3A). The randomi-
sation scheme is then exactly as before, except
that half of the randomised blocks are now as-
signed to Batch A, and the other half to Batch
B.
Assume that for some unknown reason, some-
thing is different for the second batch, resulting
in increased protein abundance measurements
(Figure 3C). Each batch can now be seen as
a separate experiment: the difference between
treatment and placebo can be calculated in
Batch A, and similarly in Batch B (Figure 3D).
In both batches the treatment effect is close to
the ‘true’ difference (Figure 3B), even though
the measured abundances are different.
When the experiment consists of multiple
batches, they will undergo the same experimen-
tal protocol at different points in time and/or
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Figure 3: Randomisation to account for
batches. A: Sample allocation order for sub-
jects receiving placebo (black, subjects 1 – 10)
and treatment (red, subjects 11 – 20). B: True
abundance if no batch effect. Dashed lines in-
dicate group means for all placebo subjects and
all treatment subjects, considered to be the
true group means. C: Simulated batch effect.
D: Observed abundances = true abundance +
batch effect. Dashed lines indicate group means
within the batches.
space. Every step of the protocol may then in-
troduce variation that is specific for each batch.
If samples are moved across batches between
processing steps, each processing step has its
own specific sample-to-batch allocation. Then,
each processing step will have its own batch
effect, and each of these will have to be esti-
mated, unnecessarily increasing the complexity
of the model. It is instead recommended to
keep the same batches throughout the exper-
iment, so that possible batch effects from dif-
ferent processing steps are combined into one
overall batch effect.
If different processing steps of the protocol
have different size constraints, i.e. one step re-
quires more batches than another, being able to
combine the smaller batches into larger batches
without having to split the smaller batches is
ideal. For example, when one experimental
step can process 12 samples at once, while an-
other step can process 24 samples at once, two
batches from the first step can be combined
for the second processing step. When this is
not possible, it makes most sense to set up the
batches according to the smallest constraints,
and keep these batches throughout.
As a general advice, to reduce the complexity
of experimental design, execution, and down-
stream analysis, it is recommended to keep the
distribution of control variables as simple as
possible. Note that this also applies to sam-
ple characteristics such as sex, age, and patient
ancestry. For example, if one has to use two
batches and is not interested in the association
of the response with the sex of the patients, it is
perfectly fine, and even recommended, to pro-
cess Male and Female samples separately, hence
confounding batch allocation with sex, thus re-
ducing the complexity of the model.
Multiple treatment variables
When the effect of an explanatory variable, e.g.
sex, on the response is of interest, it must be
considered as one of the treatment variables.
Similar considerations then hold as for the con-
trol variables, i.e. to be able to estimate the
effect of the treatment variables, they should
not be confounded with each other, nor with
the control variables.
In a setting with multiple treatment vari-
ables, one can also be interested in estimating
interactions between the treatment variables.
These interactions then become another treat-
ment variable, and it is important to make sure
that these are also not confounded with any
of the other variables. Hence, with sex and
treatment as the treatment variables, one has
to make sure that the effects of both sepa-
rately and their interaction can be estimated.
For this, all combinations of sex and treatment
should be present in the experiment. Addi-
tionally the comparison between these combi-
nations should not be confounded by a control
variable. Here again, the latter can be achieved
using block randomisation.
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For example, given 24 patients equally di-
vided into two treatment levels, Placebo and
Treatment, and two sexes, Female and Male,
there are now four groups of six subjects rep-
resenting each treatment-sex combination (1:
Placebo Female, 2: Placebo Male, 3: Treatment
Female, 4: Treatment Male). To make sure that
the groups are balanced over the experimental
design, we make six blocks of four subjects, one
of each group, and within each block we ran-
domly order the groups. Subsequently, we ran-
domly allocate subjects to the blocks based on
their group.
In case all samples cannot be processed to-
gether, one first creates the batches, and sub-
sequently performs block randomisation within
each batch. For example, say we have to process
the above samples in two batches. Given that
we are interested in all comparisons between
the treatment-sex combinations, we make two
batches of 12 samples, each batch containing
three subjects of each group (Figure 4). This
way, the batches are balanced in terms of the
subject-characteristics that we use in the ana-
lytical model.
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Figure 4: Example of block randomisation with
two variables and two batches. Treatment vari-
ables are treatment and sex, with treatment
having two levels: Placebo (black) and Treat-
ment (red). All combinations of treatment vari-
ables are represented by one subject in each
block. Within these constraints subjects are
randomly assigned to a block and the order of
the subjects in each block is randomised.
In contrast to the case where sex is a con-
trol variable, putting all Males in one batch and
all Females in the other should now clearly be
avoided: sex and batch would be complete con-
founders, rendering impossible the comparison
between Males and Females. Similarly, the in-
teraction between sex and treatment would be
lost.
With an increasing number of variables, the
model becomes increasingly constrained. Given
that one always has only a limited number of
samples, variables thus need to be prioritised.
The general advice from Box et al.7 “Block
what you can and randomize what you can’t”,
implies that there is only so much one can con-
trol for. Especially in proteomics studies, with
generally large heterogeneity between subjects,
one has to be careful not to block so heavily, and
to include so many variables, that some combi-
nations of treatment and control variables occur
in only a very limited subset of subjects.
Further considerations
The strategies outlined for the theoretical set-
tings above can easily be extended to more elab-
orate situations. However, as for all methods,
implementing block randomisation can quickly
become challenging in real-world situations. In
this section, special considerations are intro-
duced for situations where the reality of the ex-
periment poses challenges in experimental de-
sign.
Continuous variables and fuzzy
categories
Most of the variables inspected so far have di-
vided the samples into non-overlapping cate-
gories, this will however not always be the case.
Often, variables are continuous or categories are
overlapping, such as age or disease state, re-
spectively. In both cases categorisation is com-
monplace, but can be problematic. Categories
that span a large number of values can lead
to relatively large differences between subjects
within a category, while the differences between
subjects at the edges of neighbouring categories
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will be small. On the other hand, in a large
enough study the randomisation should miti-
gate this problem. Additionally, a substantial
number of subjects per category is a require-
ment to still be able to randomise subjects. If
each subject ends up being its own category,
randomisation will no longer be possible.
In cases where categorisation is problematic,
one can perform matching for the purposes of
blocking, i.e. subjects that are similar accord-
ing to a given variable e.g. age or disease state,
but belong to different groups with respect to
all other variables, are treated as a single group
for the purposes of block randomisation (see for
example Sekhon21). Note that the categorised
version is solely created for block allocation,
and the final analysis still uses the original vari-
able.
When batch-size is smaller than
the number of groups
When the number of variables increases, the
batch-size may become smaller than the num-
ber of groups. It then becomes important to
distribute samples across batches in a way that
makes it possible to calculate the differences of
interest. This generally means that one has to
prioritise some group-comparisons over others.
The more often a pair of groups occurs together
in a batch, the better one can estimate the given
difference. On the other hand, when a pair of
groups never occurs together in a batch, but
share a batch with a common other group, the
difference can be calculated through this com-
mon other group. For general strategies on how
to construct batches in a way that the differ-
ences of interest are estimable, see e.g. Lawson9
or Box et al.7
Mitigation of batch effects using
reference samples
An approach that maintains comparability be-
tween samples is to introduce a common refer-
ence. For example, in targeted proteomic anal-
yses, one spikes a known amount of the heavy
version of a peptide/protein, for use as a ref-
erence to infer the concentration of the pep-
tide/protein present in each sample, and hence
compare the abundance of the specific pep-
tide/protein across the samples.11,22
A similar approach can also be used in un-
targeted settings, both with and without la-
bels,12,23,24 where one sample is used as a stan-
dard throughout the experiment. Having a
common reference makes samples more easily
comparable across the different settings (e.g.
batches, days of analysis, and instruments) by
providing a common baseline. However, this
only works for processing steps that the ref-
erence sample shares with the other samples
in the relevant batch, and poses challenges in
terms of missing value and dynamic range that
are beyond the scope of this article.
The use of common reference samples can al-
leviate many challenges concerning batch ef-
fects. However, it is not always possible or de-
sirable to include a common reference. For ex-
ample, there may be constraints with regards
to the available resources, e.g. the acquisition
of heavy peptides for absolute quantification
in targeted studies can be very expensive, and
similarly, for large studies that run for an ex-
tended period of time, it is often not feasible
to create a reference sample with a comparable
composition relative to the experimental sam-
ples and that is large enough to last through
the entire study.
Closing remarks
Proteomics has many aspects that ought to be
taken into account when designing and plan-
ning experiments. The complexity of the sam-
ples, the proteome, and the analytical tech-
niques employed make proteomics experiments
particularly challenging. Especially in larger
studies, the labour intensive sample prepara-
tion often means that the experiment has to be
split into multiple batches. It is therefore im-
portant to design the experiment in such a way
that variables and batches are not confound-
ing. Each batch should as much as possible
be its own small experiment. When the size of
the batches is insufficient to achieve this, it is
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essential to make sure that the utilised exper-
imental design can give answers to the scien-
tific questions asked. To ensure this, and min-
imise the bias due to unobserved variables as
much as possible, one should therefore block
variables and randomise subjects, in the differ-
ent batches, and use this restricted random al-
location to process samples in the lab and on
the mass spectrometer.
It is important to underline that the chal-
lenges posed by the handling of multiple vari-
ables can only be answered if the scientific
project is rigorously defined, with response,
treatment, and control variables clearly iden-
tified before the samples are collected. Given
the multidimensional and multidisciplinary na-
ture of modern omics projects, it is essential
that experts with the necessary expertise are in-
volved early in the experimental design, to pre-
vent confounding effects. Finally, while consid-
erations of power are beyond the scope of this
article, it cannot be stressed enough that an ad-
equate number of samples is paramount, both
for correct experimental design and to ensure
that the research questions can be answered.
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